10 Best AI Specialty Drug Prior Authorization Tools

Quick answer: The best AI specialty drug prior authorization tools in 2026 are the ones that handle the unique weight of biologics and infusions — high cost, the medical-versus-pharmacy benefit split, and recurring reauthorization. Honey Health leads for practices that want specialty-drug PAs submitted and chased across both benefits and every payer inside their existing EHR. SamaCare and Mandolin bring AI to buy-and-bill and infusion; Tandem, Develop Health, and Latent Health handle pharmacy-benefit biologics and advanced-therapy access; Silna manages recurring authorizations; Humata and Coral automate broadly; and Banjo is the payer-side AI. The right pick depends on your benefit mix and how much of the specialty workflow you need automated.

Specialty drugs are the most expensive, most complex corner of prior authorization, which makes them fertile ground for AI — and a place where AI's limits matter. A biologic or infusion can carry thousands of dollars of exposure, run through either the medical or the pharmacy benefit, demand detailed clinical justification, and require reauthorization every few months to keep a patient on therapy. AI tools now read the chart, predict coverage, assemble that justification, submit the request, and track the renewals, compressing work that used to consume specialty coordinators for hours per patient.

But "AI specialty drug prior authorization" isn't one product. The category splits the same way the underlying workflow does — between the buy-and-bill medical benefit and the pharmacy benefit — and it splits again between the provider side getting drugs approved and the payer side deciding. The AI-native tools cluster differently along those lines, and the right shortlist depends on which drugs you handle and which benefit they run through.

This guide ranks the AI-native tools for specialty drug PA in 2026, with a clear best-fit and an honest read on where each one stops. It's the AI spoke of our specialty drug PA software guide and part of the broader AI prior authorization hub; for retail medication, see the AI medication PA tools companion.

Last updated: June 2026.

Where AI helps most in specialty drug PA

Specialty drug PA has several distinct steps, and AI adds different amounts of value at each. At the front, coverage and benefit determination — figuring out whether a drug needs a PA and on which benefit — is where AI tools like Develop Health and Myndshft-style determination shine, predicting requirements before a request is even filed. In the middle, documentation assembly is where large language models earn their place, pulling diagnosis, prior therapies, and lab values from the chart into the clinical justification a payer wants for an expensive therapy.

The back end is where specialty drugs differ most from other PA work, and where AI is still maturing. Specialty therapies require recurring reauthorization, so a tool that tracks expirations and re-files renewals — the way Silna does for recurring authorizations — prevents the therapy interruptions that hurt patients and create reimbursement gaps. And across all of it, the most useful AI knows when to escalate: a high-dollar specialty denial is exactly the kind of case that belongs with a human, not an automated push-through.

How we evaluated these AI specialty drug PA tools

We included tools built around modern AI — large language models, machine learning, or autonomous agents — that do real specialty-drug PA work, serve US healthcare in 2026, and are HIPAA-compliant. We left the incumbent ePA rails to our general guide. The dimensions that separated the field:

• Which benefit it serves — buy-and-bill medical, pharmacy benefit, or both?
• Which side it serves — the practice submitting, or the payer deciding?
• Workflow depth — coverage, PA, and reauthorization, or PA alone?
• Autonomy and judgment — does it submit and chase, draft, or decide — and does it escalate the hard cases?
• EHR and portal fit — does it operate across the payers and benefits you use?

There's no universal winner. An infusion center automating J-code authorizations and a dermatology group prescribing pharmacy-benefit biologics need different tools, so each entry carries a clear best-fit and an honest note on its limits.

AI specialty drug PA tools at a glance

The 10 best AI specialty drug PA tools in 2026

1. Honey Health — best for end-to-end specialty PA across both benefits

Honey Health runs specialty drug PA as an AI staff member that works the request regardless of which benefit a therapy falls under. The agent identifies the PA requirement in the EMR, assembles the clinical justification — diagnosis, prior therapies, lab values — logs into the right payer portal whether the drug runs through the medical or pharmacy benefit, submits, monitors status across the days a payer takes, and writes the decision back to the chart. It uses agentic browser automation rather than a built integration, so it operates the payer portals and the 20+ EHRs your staff already use, which matters in specialty care where a practice routinely straddles both benefits.

The unifying value is real for specialty practices: instead of running a buy-and-bill tool alongside a pharmacy-benefit tool, one agent works a J-code infusion authorization and a pharmacy-benefit biologic the same way, chasing each to a confirmed decision. Pricing runs per completed PA — about $1.50 to $2 including follow-up — and Honey reports practices offsetting roughly one full-time coordinator per 25 new PAs a day, 80 to 95 percent less manual effort, and 99.8 to 99.9 percent task accuracy, with complex, high-dollar cases routed to a person rather than forced through.

Honey works the provider's side and doesn't replace the deep hub-services and patient-assistance layers some specialty launches require, and it's a newer name than the established specialty vendors here, so confirm coverage for your drug and payer mix. For specialty practices that want one AI agent working both medical and pharmacy-benefit drug PAs end to end inside their existing EHR, it's the most unified option on this list.

2. SamaCare — best for AI in buy-and-bill (J-code) drug PA

SamaCare brings AI to the medical-benefit side, automating prior authorization for the J-code injectables and infusions a practice buys, administers, and bills. Built on AI trained on more than two million prior authorizations, it handles the buy-and-bill workflow specialty practices struggle with most and reports processing billions of dollars in drug authorizations, with a $17 million Series B in 2024 fueling adoption across rheumatology, oncology, ophthalmology, and dermatology.

Its concentration on buy-and-bill is what makes it sharp there and quiet on pharmacy-benefit ePA, and it reads more as an AI-accelerated workflow platform than a fully autonomous agent that chases every case unattended. For specialty practices whose pain is concentrated in medical-benefit, J-code drugs, that focus is the attraction. Best for specialty practices automating buy-and-bill drug authorizations with AI.

3. Mandolin — best for agentic infusion and specialty access

Mandolin is an agentic platform for specialty-drug administration at infusion centers and specialty pharmacies, where AI-driven prior authorization sits inside a wider flow spanning benefits investigation, patient cost, co-pay assistance, and 340B pricing. It raised a combined $40 million in 2025 across more than 700 clinic locations, positioning itself as an AI operating system for specialty-drug access rather than a PA point tool.

The breadth is its signature and its boundary: Mandolin goes deep on specialty and infusion workflows and isn't built for general retail-pharmacy PA, so it fits organizations whose business is specialty administration. For an infusion center that wants AI handling PA inside the full access workflow, it's hard to match. Best for infusion centers and specialty pharmacies that want agentic PA inside complete specialty-drug access.

4. Tandem (Forus) — best for AI biologic PA at prescription

Tandem, through Forus, automates biologic and medication prior authorization from the prescription written in the EHR — generating the form, submitting, following up, and handling appeals, plus pharma patient-assistance enrollment — and it's free to providers and patients, funded through pharma partnerships. It reached a reported $137 million in funding and a $1 billion valuation in early 2026, with strong adoption in GI, dermatology, and rheumatology, the specialties biologics dominate.

Forus does biologic and medication PA and nothing else, and its pharma-funded model ties its economics to drug access, which buyers should weigh against a neutral, practice-paid tool. For a specialty group with heavy pharmacy-benefit biologic volume that wants those authorizations handled by AI at no software cost, the trade often makes sense. Best for free, AI-driven biologic PA at the point of prescription.

5. Develop Health — best for AI coverage and PA for biologics

Develop Health is a GenAI platform that predicts a drug's coverage, cost, and requirements at the moment of prescription, then automates benefit verification, the PA, and payer follow-up, auto-filling forms from EHR data. It raised $14.3 million in 2025 and continues expanding EHR and PBM integrations, with strength on the pharmacy-benefit side where specialty biologics are prescribed.

It concentrates on the pharmacy benefit, so a practice with meaningful buy-and-bill volume covers the medical side elsewhere, and its value peaks where prescribers act on real-time coverage signals at the visit. The coverage-prediction front end is its standout, answering whether a biologic will be covered before the work begins. Best for AI-driven coverage and PA on pharmacy-benefit biologics.

6. Silna Health — best for recurring specialty and therapy authorizations

Silna Health is AI-native for therapy-heavy and recurring-authorization specialties — ABA, PT/OT, speech, behavioral health, and the recurring auths specialty care generates — managing renewals, expirations, payer-specific forms, follow-ups, and appeals, with a pre-submission AI review of clinical documentation. It raised $27 million and reports supporting more than 150,000 patients, with reauthorization management as a core strength.

Silna is tuned to recurring authorization patterns rather than one-time buy-and-bill or retail drug PA, so its fit is specific to organizations whose burden is renewals. That reauthorization focus is precisely what many specialty programs need, since a lapsed authorization interrupts therapy. Best for specialty and therapy organizations managing recurring authorizations and renewals.

7. Humata Health — best for touchless PA across drugs and procedures

Humata Health automates prior authorization across specialty drugs and medical procedures for both providers and payers, with AI policy matching, automated statusing, and gold-carding aimed at roughly 90 percent touchless authorizations. Its roots are in Olive AI's prior-authorization business, and it raised about $25 million in 2024, with specialty drugs and procedures both in scope.

Spanning drugs and procedures across both sides gives Humata reach, and it lands most naturally with enterprise revenue-cycle teams and health systems that can deploy it broadly rather than a single specialty clinic. A smaller specialty practice may find it heavier than a focused tool, and its touchless rate depends on the payer and drug mix. Best for health systems and large groups wanting touchless AI PA spanning specialty drugs and procedures.

8. Coral AI — best for drafting specialty PAs across intake

Coral AI replaces rules-based RPA with AI across the back office, and prior authorization — extracting clinical data, reasoning over criteria, and drafting the authorization for review — runs alongside its fax and intake workflows, specialty drugs included. It raised seed funding led by Lightspeed and reports more than 500,000 workflows a month.

As a younger, seed-stage company, its footprint is still building, it isn't specialty-specific, and its PA output is often drafted for a human to review rather than fired fully autonomously — a reasonable posture for high-dollar specialty drugs, but one that keeps a person in the loop. For groups that want AI drafting specialty and other PAs as part of a broader intake-automation effort, Coral fits. Best for AI-drafted specialty PAs inside a wider intake-automation effort.

9. Latent Health — best for accelerating advanced-therapy access

Latent Health builds AI to accelerate medication access, streamlining prior authorizations and speeding patient access to advanced therapies for health systems and specialty pharmacies, and it partners with CoverMyMeds on FHIR-based PA automation. Its focus on advanced therapies — the newest, costliest, and most access-challenged specialty drugs — distinguishes it from broader medication-PA tools.

As a newer, focused entrant, its footprint is smaller than the established specialty vendors, and its orientation toward health systems and pharmacies means a small practice should confirm fit. Where it stands out is the advanced-therapy access problem specifically, paired with FHIR-based automation. Best for health systems and pharmacies accelerating access to advanced and cell-and-gene therapies.

10. Banjo Health — best for AI drug PA decisioning for plans

Banjo Health is the payer-side counterpart here: an AI platform helping health plans and PBMs manage the medical and pharmacy PA workflow from request through clinical review to appeals, reading submitted records against payer criteria — specialty drugs on both benefits included. It's built for the decisioning end of the transaction, with a single workflow across the PA lifecycle.

For a specialty practice, that orientation is the boundary: Banjo isn't a tool a provider buys to submit drug PAs — it's the AI on the other side of the request. Its strength is giving a plan one workflow from intake to appeal for the high-cost specialty drugs that drive PA spend. Best for health plans and PBMs modernizing their own specialty-drug PA and review.

How to choose an AI specialty drug PA tool

Start with the benefit split, because it shapes the whole decision. Buy-and-bill, medical-benefit volume points toward SamaCare and Mandolin; pharmacy-benefit biologics point toward Tandem, Develop Health, and Latent Health; recurring authorizations point toward Silna. If you straddle both benefits — as many specialty practices do — a broad AI agent like Honey Health's that works whichever path a drug takes spares you from running two systems and reconciling their queues.

Then weigh your seat. If you're a practice or specialty pharmacy, the payer-side decisioning tool (Banjo) isn't yours to buy; your shortlist is the provider-side AI that submits and chases. If you're a health plan or PBM, that decisioning layer is exactly what you're after, and the question becomes how well it explains a specialty denial — because the dollar amounts make those denials consequential.

Account for the full lifecycle, not just the first authorization. Specialty drugs live on reauthorization, so a tool that tracks expirations and re-files renewals protects continuity of therapy in a way a submit-once tool does not. And given the cost of these drugs, favor AI that confirms an authorization rather than merely submitting it, and that escalates the high-dollar edge cases to a human instead of pushing everything through.

Finally, weigh breadth against depth and integration cost. The specialty specialists go deep on a slice; a broad agent trades some depth for working every drug and benefit in one place, and one that runs on agentic browser automation avoids the per-EHR integration tax that slows time-to-live. For the full field including the incumbent ePA rails and hub-services platforms, see our specialty drug PA software guide.

Frequently asked questions

What is AI specialty drug prior authorization?

AI specialty drug prior authorization uses machine learning or autonomous agents to do the PA work behind biologics and infusions — predicting coverage, assembling clinical justification, submitting to the payer, chasing status, and tracking reauthorization. On the provider side it submits and chases; on the payer side it reviews and decides. The two are different products at opposite ends of the same high-cost request.

Does AI handle the buy-and-bill versus pharmacy-benefit split?

Some tools specialize by side — SamaCare for buy-and-bill, Tandem and Develop Health for pharmacy-benefit biologics — while others span both. A broad agent like Honey Health works a request regardless of which benefit a drug runs through, since it operates the relevant payer portal directly. Practices straddling both benefits often prefer a tool that covers them rather than running two.

Can AI manage specialty drug reauthorizations?

Yes, and it's one of AI's most valuable jobs here. Specialty therapies require recurring reauthorization, and tools built for it — Silna for recurring authorizations, and broad agents that track status and renewals — flag expirations and re-file before therapy lapses. Because a missed renewal interrupts treatment and creates a reimbursement gap, reauthorization tracking is a feature worth prioritizing for specialty drugs.

Is AI safe to use on high-cost specialty drug PAs?

The safety comes from design. Because specialty denials carry real money and clinical weight, the better AI tools keep a human in the loop on high-dollar and ambiguous cases rather than forcing them through, and they confirm an authorization instead of just submitting it. Honey Health, for instance, reports 99.8 to 99.9 percent task accuracy and routes complex, high-dollar cases to a person.

Is provider-side or payer-side AI right for my specialty practice?

A specialty practice needs provider-side AI that submits and chases drug authorizations — Honey Health, SamaCare, Mandolin, and most of this list. Payer-side AI (Banjo) is licensed by health plans and PBMs to review those requests. A practice can't fix its authorization queue with a payer tool, so identify your side before building a shortlist.

How much do AI specialty drug PA tools cost?

Pricing varies by model. Honey Health charges per completed authorization (about $1.50 to $2); Tandem's Forus is free and pharma-funded; others price by subscription, contract, or program, and several don't publish rates; payer tools are sold to plans. Given how expensive specialty drugs are, weigh any price against the reimbursement risk and coordinator time a single mishandled authorization represents.

AI is transforming specialty drug prior authorization most where the work is heaviest — coverage prediction, documentation, and the reauthorizations that keep patients on therapy — but the benefit split still decides your shortlist. Map your drugs to the medical or pharmacy side, favor AI that confirms authorizations and escalates the costly edge cases, and for a specialty practice that wants both benefit paths worked end to end inside its existing EHR, Honey Health is a strong starting point.